

GC8 Syphilis Toolkit

User Guide

Purpose

This toolkit helps country teams and their technical assistance partners integrate dual HIV/syphilis rapid diagnostic tests and benzathine penicillin G into Global Fund GC8 (2027–2029) funding proposals. It covers the documentation GC8 requires: commodity quantification, landed cost budgets, evidence justification for reviewers, and pre-submission verification.

The toolkit works for countries procuring dual tests for the first time through GC8 and for countries that included dual tests in GC7 and need to sustain or scale that commitment in the next cycle.

For countries evaluating HIV/syphilis/hepatitis B triplex tests, the toolkit also includes triple test quantification support in the Calculator and guidance on triple test procurement considerations in the Checklist and Evidence Brief.

What Is Included in the Toolkit?

Tool	When to Use	Key Outputs
Quantification & Budget Integrated Calculator	Once ANC population, syphilis prevalence, and coverage targets are confirmed	3-year quantities; landed cost budget; funding scenario and coverage gap analysis; estimated adverse outcomes averted
Impact Evidence Package	During and after country dialogue; when writing the funding narrative	Evidence summaries; narrative templates; country adoption examples; Quick Reference table; Evidence Brief annex
Evidence Brief	Country dialogue, CCM meetings, MOH discussions, donor advocacy	One-page evidence summary combining burden, efficacy, cost-effectiveness, and GC8 strategic fit
Syphilis Integration Checklist	Open first; return at each phase transition and before submission	Phase-by-phase task list with syphilis-specific flags, toolkit cross-references, and pre-submission consistency check

Quantification & Budget Integrated Calculator

An Excel workbook that calculates commodity quantities, total landed costs, and a 3-year budget for dual HIV/syphilis RDTs, triple HIV/syphilis/HBV tests (where applicable), and BPG. Enter country data and coverage targets. The tool generates procurement quantities, buffer stock, landed cost documentation, a funding scenario analysis, and estimated adverse outcomes averted. It covers pregnant women and, optionally, other populations such as PLHIV or PWID.

Before opening the calculator, have the following ready:

- Annual number of pregnant women (WHO GHO, UNAIDS, or national health statistics)
- Syphilis prevalence among pregnant women (WHO STI Dashboard, country surveillance, or recent surveys)
- Current syphilis screening and treatment coverage (national HMIS or WHO GAM reports)
- Year 1–3 target screening and treatment coverage

- Existing dual test procurement volumes and sources, if any

Impact Evidence Package

An evidence summary organized around the key sections of a GC8 proposal. Each section presents the relevant published evidence and tells you exactly where to use it in the application. Content draws on peer-reviewed studies, WHO guidance, and global market data.

- **Section 1: The Strategic Case.** Value for money, integration into existing HIV and ANC platforms, and affordability.
- **Section 2: The Evidence Base.** Burden and screening gap data, diagnostic evidence from SSA RCTs and real-world studies, BPG treatment efficacy data, and cost-effectiveness literature.
- **Section 3: Country Adoption Examples.** Before-and-after adoption outcomes for Cameroon, Liberia, and Zambia. Use to support CCM discussions and MOH advocacy.
- **Sections 4 and 5: Narrative Templates and Quick Reference.** Three proposal-ready templates (Programmatic Gap Table narrative, Budget Justification, Strategic Alignment) with bracketed placeholders for country data, plus a single-table evidence summary for rapid citation across proposal sections.
- **Annex: Evidence Brief.** One-page companion for country dialogues and CCM meetings. Available as a standalone document.

Evidence Brief

A standalone one-page document for country dialogues, CCM meetings, MOH discussions, and donor advocacy. It covers the scale of the problem, the solution, efficacy evidence, cost-effectiveness, and GC8 strategic fit in a format accessible to non-technical audiences.

Syphilis Integration Checklist

An actionable guidance document that follows the GC8 proposal development process across four phases: Before Country Dialogue, Country Dialogue and Gap Analysis, Application Development, and Pre-Submission Review. Items marked **S** are syphilis-specific. The Toolkit Support column identifies which tool covers each step.

Open this tool first. It gives you a working schedule and the full sequence of required steps before you open any other tool. Return to it at each phase transition and before final submission. The Phase 4 cross-component consistency check verifies that dual test and BPG quantities appear in all five required locations: programmatic gap analysis, HPMT, supply chain quantification, Detailed Budget, and Performance Framework.

Note on triple testing: for countries evaluating triple HIV/syphilis/HBV RDTs, adapt dual test checklist items to include the triple test, confirm in-country registration status, and identify which partners plan to procure it.

Suggested Order for Using the Tools

#	Tool	When	What It Produces
1	Syphilis Integration Checklist	Open and review first	Full application timeline and phase-by-phase task list
2	Quantification & Budget Integrated Calculator	Once population, prevalence, and coverage targets are confirmed	3-year quantities, budget, impact estimates, funding scenario analysis

#	Tool	When	What It Produces
3	Impact Evidence Package	During and after country dialogue	Evidence framing and proposal-ready narrative templates
4	Evidence Brief	Country dialogue, CCM meetings, MOH and donor discussions	One-page advocacy document

For countries introducing dual tests for the first time in GC8, allow more time on policy prerequisites and evidence framing in Phases 1 and 2 before moving to quantification. For countries with existing dual test procurement, the Calculator can move quickly once data inputs are verified.

How the Tools Fit Together

Tool	Feeds Into
Quantification & Budget Calculator	Quantities and unit costs transfer directly into the HPMT. Budget totals feed into the Detailed Budget. Executive Summary figures appear in the funding narrative and programmatic gap table.
Impact Evidence Package	Narrative templates integrate into the GC8 funding narrative. Evidence summaries support the programmatic gap analysis and value-for-money section. Evidence Brief (annex) can be extracted for standalone advocacy use.
Evidence Brief	Used independently in country dialogues, CCM meetings, and donor discussions.
Syphilis Integration Checklist	Verifies that dual test and BPG outputs from all tools appear consistently across the programmatic gap analysis, HPMT, Detailed Budget, Performance Framework, and funding narrative before submission.

Adapting the Tools to Country Context

All tools accept country-specific inputs. Default values are included where data is not yet available, but these should be replaced with actual country figures before a proposal is submitted.

Tool	What to Adapt for Each Country
Quantification & Budget Calculator	<p>Select the country from the dropdown in Section 1, or "Other" if not listed.</p> <p>Verify all auto-populated figures against the most recent national surveys or program data before finalizing. Adjust landed cost components (freight, customs, distribution) for the country's specific logistics context.</p> <p>Set the dual test share for each year to reflect whether the country is procuring dual tests only or a mix of dual and triple tests.</p>
Impact Evidence Package	Replace bracketed placeholders in narrative templates with country-specific figures.
Evidence Brief	Use as-is for most audiences. Supplement with national syphilis prevalence and coverage figures for MOH or CCM presentations requiring country-specific data.

Tool	What to Adapt for Each Country
Syphilis Integration Checklist	Update submission deadline dates to match the country's GC8 application window. Use the check column to keep track of outstanding items..

Additional Resources

Resource	Notes
GC8 HIV Prioritization Guidance	Core strategic framing document. Explicitly endorses HIV/syphilis dual RDTs as the first-line ANC test and lists BPG as a scaling priority. Use as the primary policy anchor in all GC8 narrative sections.
WHO Triple Elimination Country Guidance	Programmatic context and country readiness frameworks for triple elimination of HIV, syphilis, and hepatitis B.
WHO Consolidated STI Operational Handbook	Consolidates all WHO normative guidance on STI prevention, diagnosis, treatment, and surveillance. Relevant for countries integrating syphilis into primary health care.
UNICEF Supply Catalogue	BPG pricing reference. BPG 2.4 MIU: \$0.39–\$3.19 per dose. Use for BPG unit cost budgeting in the Calculator.
Global Fund PPM Reference Pricing	Negotiated pricing for dual HIV/syphilis tests. The Calculator auto-populates these prices; reference directly to verify or update unit costs.
Global Fund Price & Quality Reporting Database	Historical procurement data and supplier performance for benchmarking and supplier identification.
WHO Congenital Syphilis Estimation Tool	Country-level burden modeling tool. For teams that want to run their own congenital syphilis estimates.
CHAI Integrated Screening Market Memo	Market information on triple HIV/syphilis/HBV tests. Relevant for countries evaluating dual vs. triple test procurement.